Patients who underwent stereotactic ablative radiotherapy (SABR) for medically inoperable early-stage non-small cell lung cancer (NSCLC) had a pathologic complete response (pCR) rate that was lower than expected, according to a study published in JAMA Oncology. The researchers undertook the study… Read More
cancer cells
Patients with advanced biliary tract cancer (BTC) may potentially be treated with tremelimumab in combination with microwave ablation, according to a study published in Hepatology. The authors had previously seen promising results by combining tremelimumab with radiofrequency ablation for… Read More
liver cancer
Radioembolization with yttrium-90 (Y-90) microspheres may be an effective second-line therapy for patients with liver metastases from pancreatic adenocarcinoma, according to a study published in the Journal of Vascular and Interventional Radiology. The retrospective study involved 33 patients with… Read More
DOSIsoft, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, is pleased to announce it has received on March 7th, 2019, from the US Food and Drug Administration (FDA), the 510(k) clearance to market PLANET® Onco Dose software, for its Oncology and Yttrium-… Read More
cancer cells
Stereotactic ablative radiation therapy (SABR) may help to improve outcomes for recurrent oligometastatic cancer and is accompanied by minimal acute and late grade 3 toxicity, according to a multicenter, phase 2 trial. “Oligometastatic disease has emerged as a potentially curable state in the… Read More
Researchers have developed a prognostic score that can help to stratify candidates for transarterial chemoembolization (TACE), according to a study published in the Journal of Hepatology. “There lacks a prognostic model specifically developed for recommended or ideal TACE candidates with HCC (BCLC… Read More
Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) may have improved overall survival (OS) after being treated with dual modality radiation with external beam radiation therapy (EBRT) and transarterial radioembolization (TARE). Researchers reported their findings in the… Read More
Results of a phase II trial suggest that image-guided high-dose-rate (HDR) brachytherapy (iBT) may lead to better outcomes than conventional transarterial embolization (cTACE) in treating unresectable hepatocellular carcinoma (HCC). The authors were interested in exploring the value of iBT in… Read More
Patients with advanced renal cell carcinoma who were treated with a combination of sorafenib and cryoablation fared better than those who were treated with sorafenib alone, researchers from Tianjin, China, reported. Cryoablation has been studied in early-stage renal cell carcinoma, but there have… Read More
Transarterial radioembolization with yttrium-90 (TARE-Y90) may be worth considering as an adjunctive therapy for pediatric patients with unresectable hepatic malignancies, according to a study published in Pediatric Blood Cancer. “TARE-Y90 of unresectable primary liver malignancy is both… Read More